Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor

Leuk Lymphoma. 2004 Nov;45(11):2353-4. doi: 10.1080/10428190412331272712.

Abstract

A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / biosynthesis
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzamides
  • Cyclophosphamide / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Female
  • Gastrointestinal Stromal Tumors / drug therapy*
  • Humans
  • Imatinib Mesylate
  • Lymphoma / metabolism
  • Lymphoma, B-Cell, Marginal Zone / drug therapy*
  • Middle Aged
  • Piperazines / administration & dosage*
  • Prednisolone / administration & dosage
  • Pyrimidines / administration & dosage*
  • Recurrence
  • Rituximab
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Imatinib Mesylate
  • Cyclophosphamide
  • Prednisolone

Supplementary concepts

  • VAP-cyclo protocol